期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Telomerase-related advances in hepatocellular carcinoma:A bibliometric and visual analysis 被引量:1
1
作者 Hai-Yang Li Lin-Lin Zheng +9 位作者 Nan Hu Zhi-Hao Wang Chang-Cheng Tao Ya-Ru Wang Yue Liu zulihumaer aizimuaji Hong-Wei Wang Rui-Qi Zheng Ting Xiao Wei-Qi Rong 《World Journal of Gastroenterology》 SCIE CAS 2024年第9期1224-1236,共13页
BACKGROUND As a critical early event in hepatocellular carcinogenesis,telomerase activation might be a promising and critical biomarker for hepatocellular carcinoma(HCC)patients,and its function in the genesis and tre... BACKGROUND As a critical early event in hepatocellular carcinogenesis,telomerase activation might be a promising and critical biomarker for hepatocellular carcinoma(HCC)patients,and its function in the genesis and treatment of HCC has gained much attention over the past two decades.AIM To perform a bibliometric analysis to systematically assess the current state of research on HCC-related telomerase.METHODS The Web of Science Core Collection and PubMed were systematically searched to retrieve publications pertaining to HCC/telomerase limited to“articles”and“reviews”published in English.A total of 873 relevant publications related to HCC and telomerase were identified.We employed the Bibliometrix package in R to extract and analyze the fundamental information of the publications,such as the trends in the publications,citation counts,most prolific or influential writers,and most popular journals;to screen for keywords occurring at high frequency;and to draw collaboration and cluster analysis charts on the basis of coauthorship and co-occurrences.VOSviewer was utilized to compile and visualize the bibliometric data.RESULTS A surge of 51 publications on HCC/telomerase research occurred in 2016,the most productive year from 1996 to 2023,accompanied by the peak citation count recorded in 2016.Up to December 2023,35226 citations were made to all publications,an average of 46.6 citations to each paper.The United States received the most citations(n=13531),followed by China(n=7427)and Japan(n=5754).In terms of national cooperation,China presented the highest centrality,its strongest bonds being to the United States and Japan.Among the 20 academic institutions with the most publications,ten came from China and the rest of Asia,though the University of Paris Cité,Public Assistance-Hospitals of Paris,and the National Institute of Health and Medical Research(INSERM)were the most prolific.As for individual contributions,Hisatomi H,Kaneko S,and Ide T were the three most prolific authors.Kaneko S ranked first by H-index,G-index,and overall publication count,while Zucman-Rossi J ranked first in citation count.The five most popular journals were the World Journal of Gastroenterology,Hepatology,Journal of Hepatology,Oncotarget,and Oncogene,while Nature Genetics,Hepatology,and Nature Reviews Disease Primers had the most citations.We extracted 2293 keywords from the publications,120 of which appeared more than ten times.The most frequent were HCC,telomerase and human telomerase reverse transcriptase(hTERT).Keywords such as mutational landscape,TERT promoter mutations,landscape,risk,and prognosis were among the most common issues in this field in the last three years and may be topics for research in the coming years.CONCLUSION Our bibliometric analysis provides a comprehensive overview of HCC/telomerase research and insights into promising upcoming research. 展开更多
关键词 TELOMERASE Bibliometric analysis Telomerase reverse transcriptase PROGNOSIS Treatment Hepatocellular carcinoma
下载PDF
液滴式数字PCR检测尿路上皮癌患者尿cfDNA中FGFR3基因S249C突变的临床应用价值
2
作者 祖丽胡马尔·艾孜木阿吉 赵焕 +3 位作者 马晟 高苒 王雅茹 肖汀 《癌变.畸变.突变》 CAS 2023年第3期165-171,共7页
目的:通过非侵入性方式提取尿路上皮癌(UC)患者尿游离DNA(cfDNA),使用液滴数字PCR(ddPCR)检测尿cfDNA中成纤维细胞生长因子受体3(FGFR3)基因S249C位点突变,辅助尿脱落细胞学检查提高UC的诊断效能。方法:收集27例UC患者尿液并提取尿cfDNA... 目的:通过非侵入性方式提取尿路上皮癌(UC)患者尿游离DNA(cfDNA),使用液滴数字PCR(ddPCR)检测尿cfDNA中成纤维细胞生长因子受体3(FGFR3)基因S249C位点突变,辅助尿脱落细胞学检查提高UC的诊断效能。方法:收集27例UC患者尿液并提取尿cfDNA,采用ddPCR检测尿cfDNA中FGFR3 S249C突变情况。应用受试者工作特征曲线(ROC)评价尿cfDNA中FGFR3 S249C突变对于尿脱落细胞学诊断不明确UC患者的诊断效能。结果:UC患者尿cfDNA中FGFR3 S249C突变的检出率为25.9%(7/27)。按尿液细胞学巴黎报告系统(TPS)分类,FGFR3 S249C突变在高级别尿路上皮癌(HGUC)中检出率为18.8%(3/16),可疑高级别尿路上皮癌(SHGUC)中为50%(4/8),未见高级别尿路上皮癌(NHGUC)中为0(0/3)。FGFR3 S249C在非浸润性UC中的突变率为25.0%(1/4),在浸润性UC中为31.6%(6/19)。在尿脱落细胞学诊断为SHGUC的样本中使用ddPCR检测出的FGFR3 S249C突变对于UC有50%(4/8)的检出率,且ROC曲线下面积为0.781,95%CI(0.407,1.000),在UC诊断中起到良好的辅助作用。结论:使用ddPCR检测尿cfDNA中FGFR3 S249C突变作为一种非侵入性的检测方式可以辅助提高尿脱落细胞学诊断不明确样本的诊断效能。 展开更多
关键词 尿路上皮癌 尿游离DNA 液滴数字PCR FGFR3 S249C突变 尿脱落细胞学
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部